Acurx Pharmaceuticals, Inc 8-K, filed Oct 16, 2026
Acurx Pharmaceuticals, Inc. (ACXP)
About this 8-K
Acurx Pharmaceuticals, Inc filed this 8-K on October 16, 2026.
At its October 16, 2026 Annual Meeting, Acurx Pharmaceuticals stockholders elected David P. Luci and Jack H. Dean as Class II directors for three-year terms expiring in 2029, and ratified CohnReznick LLP as independent auditor for fiscal year ending December 31, 2026. AI summary
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS
Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including
area code: (
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
At the close of business on August 20, 2026, the record date of the Annual Meeting of Stockholders of Acurx Pharmaceuticals, Inc. (the “Company”) held on October 16, 2026 (the “Annual Meeting”), there were 5,471,297 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), outstanding and entitled to vote. At the Annual Meeting, the holders of 2,890,899 shares of Common Stock, or approximately 52.83% of our outstanding shares of Common Stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, our stockholders considered two proposals, which are described briefly below and in more detail in our definitive Proxy Statement filed with the Securities and Exchange Commission on September 1, 2026. The final voting results for each proposal are set forth below.
Proposal 1 - Election of Directors
Our stockholders elected the following directors as Class II directors to serve three-year terms expiring in 2029 by the following votes:
| Nominees | Shares Voted For |
Shares Withheld |
Broker Non-Votes |
|||||||||
| David P. Luci | 1,187,323 | 73,804 | 1,629,772 | |||||||||
| Jack H. Dean | 1,203,310 | 57,817 | 1,629,772 |
Proposal 2 - Ratification of Independent Registered Public Accounting Firm
Our stockholders ratified the appointment of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:
| Shares Voted For | Shares Voted Against | Abstentions | Broker Non-Votes | |||||||||||
| 2,877,193 | 8,473 | 5,233 | N/A |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
| Acurx Pharmaceuticals, Inc. | ||
| Date: October 16, 2026 | ||
| By: | /s/ David P. Luci | |
| Name: | David P. Luci | |